Coloplast A/S Reports Stellar Financial Performance
Coloplast A/S has announced impressive financial results for the year covering October 1, 2024, through September 30, 2025. This period reflects significant growth and steady margins, highlighting the company's resilience and dedication to its core sectors.
Growth Highlights
During the fourth quarter, the company achieved a commendable organic growth rate of 7%. The EBIT margin stood strong at 28%, although reported revenue in DKK had a negligible growth effect primarily due to adverse currency fluctuations and the divestment of its Skin Care segment.
Performance Across Business Areas
In terms of organic growth across various sectors, Ostomy Care reported a 7% increase, while Continence Care and Voice & Respiratory Care showed robust growth at rates of 9%. Wound & Tissue Repair also performed well with a 5% growth rate, underpinned by promising recent product launches. Nonetheless, sales in China were impacted by decreased consumer sentiment and intensified competition.
Insights into Specific Segments
Significant contributors to growth included Luja™, which continues to gain traction among users in Continence Care. The Voice & Respiratory Care segment benefited from consistent demand for both Laryngectomy and Tracheostomy products. The Wound & Tissue Repair sector experienced impressive progress with Kerecis exhibiting a 20% growth rate and a solid EBIT margin of 14%. However, this was countered by a 6% decline in Advanced Wound Dressings, particularly due to the return of Biatain® Adhesive dressings in China, which negatively impacted revenue around DKK 60 million in the fourth quarter.
Financial Overview for 2024/25
For the fiscal year 2024/25, Coloplast reported an organic growth of 7% and generated a total revenue of DKK 27,874 million, marking a 3% increase year-over-year. The EBIT improved by 5% to DKK 7,670 million, with the EBIT margin reaching 28%, compared to 27% in 2023.
Adjusted Earnings and Dividends
The adjusted net profit before special items rose to DKK 5,148 million, reflecting a DKK 123 million increase from the previous year. Consequently, the adjusted diluted earnings per share (EPS) before special items increased by 2% to DKK 22.84. The Board of Directors is recommending a year-end dividend of DKK 18.00 per share, leading to a total of DKK 23.00 for the year, an increase from DKK 22.00 last year.
Guidance for Future Growth
Looking ahead to fiscal year 2025/26, Coloplast A/S anticipates around 7% organic revenue growth along with a similar rate for EBIT growth, adjusting for constant currencies. The outlook includes expectations of a 4-5% growth in reported revenue, accounting for currency impacts and the residual effects of the Skin Care divestment.
Key Strategic Considerations
The anticipated EBIT growth assumes sustained momentum in Chronic Care alongside improving performance in Acute Care, particularly with the Kerecis brand recovering from prior slowdowns.
Leadership Insights
Interim CEO Lars Rasmussen expressed optimism regarding the results, emphasizing the company's capacity to retain market share across all regions, with the exception of China. "2024/25 has been a transitional year for Coloplast, and I look forward to executing our new 2030 strategy, Impact4," he stated.
Upcoming Conference Call
Coloplast will conduct a conference call to discuss the full-year results on November 4 at 11:00 CEST. Participants are encouraged to register beforehand to receive dial-in details.
Contact Information
The investor relations team is available for queries regarding the financial results. For immediate assistance, interested parties can reach out to:
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Kristine Husted Munk
Senior Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com
Frequently Asked Questions
What are the key financial results for Coloplast A/S in 2024/25?
Coloplast reported a 7% organic growth and an EBIT margin of 28%, with total revenues reaching DKK 27,874 million.
How did the different business segments perform?
Ostomy Care grew by 7%, Continence Care by 9%, and Voice & Respiratory Care also achieved 9% growth, while Wound & Tissue Repair saw an increase of 5%.
What guidance has Coloplast provided for 2025/26?
Coloplast expects around 7% organic revenue growth, with similar EBIT growth in constant currencies, accounting for some impacts from currency fluctuations and previous divestments.
What is the planned dividend for shareholders?
The Board of Directors is recommending a year-end dividend of DKK 18.00 per share, totaling DKK 23.00 for the year.
Who can I contact for more information about Coloplast?
For inquiries, you can contact Anders Lonning-Skovgaard, the CFO, or Kristine Husted Munk, Senior Director of Investor Relations, for insights.
